Trial · NCT00527878
Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome
NCT00527878, Phase 2, Terminated, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2013-02-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome. Trials, record NCT00527878. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00527878
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome
- NCT number
- NCT00527878
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- JOB's Syndrome, Hyper-IgE Recurrent Infection Syndrome, Immune Deficiency
- Interventions
- Ranitidine, Placebo
- First posted
- 2007-09-11
- Last updated
- 2013-02-04
- Results first posted
- 2013-02-04
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Infections in Subjects With HIES. | 1 year on intervention | Patients received one year of treatment medication and one year of placebo. New infections (bacterial, fungal, viral or parasitic) were defined as those requiring an addition or change of an antimicrobial (including topical, oral or intravenous therapies) or those requiring a medical procedure (i.e., incision and drainage of a skin abscess, warm soaks to aid abscess drainage or sinus drainage). |
| Secondary | New Skin Infections | 12 months placebo/12 months ranitidine | Patients reported the number of new skin infections |
| Secondary | New Lung Infections | 12 months placebo and 12 months ranitidine | Number of new infection while on placebo or study drug |
| Secondary | Clinical Severity Score | one year on ranitidine and one year on placebo | Scoring that was completed every 3 months. Clinical severity scored had outcomes that could range from 0 to 121 with 0 being the least severe and 121 being the most severe. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Infections in Subjects With HIES. | 1 year on intervention | Patients that completed both arms of the study (24 months) | infections | MEDIAN |
| SECONDARY | New Skin Infections | 12 months placebo/12 months ranitidine | Patients that completed the study | skin infections | MEDIAN |
| SECONDARY | New Lung Infections | 12 months placebo and 12 months ranitidine | Patients who completed the study | new lung infections | MEDIAN |
| SECONDARY | Clinical Severity Score | one year on ranitidine and one year on placebo | Patients who completed the study | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Infections in Subjects With HIES. | Placebo | 4 | Full Range 2 to 25 | infections | |
| Number of Infections in Subjects With HIES. | Ranitidine | 4 | Full Range 0 to 15 | infections | |
| New Skin Infections | Placebo | 1 | Full Range 0 to 14 | skin infections | |
| New Skin Infections | Ranitidine | 0 | Full Range 0 to 10 | skin infections | |
| New Lung Infections | Placebo | 1 | Full Range 0 to 4 | new lung infections | |
| New Lung Infections | Ranitidine | 0 | Full Range 0 to 4 | new lung infections | |
| Clinical Severity Score | Placebo | 9.8 | Full Range 3.2 to 27.5 | score on a scale | |
| Clinical Severity Score | Ranitidine | 8.5 | Full Range 3.5 to 30.3 | score on a scale |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Intervention 1 | STARTED | Placebo/Ranitidine | 7 | |
| Intervention 1 | STARTED | Ranitidine/Placebo | 7 | |
| Intervention 1 | COMPLETED | Placebo/Ranitidine | 5 | |
| Intervention 1 | COMPLETED | Ranitidine/Placebo | 4 | |
| Intervention 1 | NOT COMPLETED | Placebo/Ranitidine | 2 | |
| Intervention 1 | NOT COMPLETED | Ranitidine/Placebo | 3 | |
| Intervention 2 | STARTED | Placebo/Ranitidine | 5 | |
| Intervention 2 | STARTED | Ranitidine/Placebo | 4 | |
| Intervention 2 | COMPLETED | Placebo/Ranitidine | 5 | |
| Intervention 2 | COMPLETED | Ranitidine/Placebo | 4 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events78
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | sinusitis | Infections and infestations | Placebo | 4 | 11 | |
| other | sinusitis | Infections and infestations | Ranitidine | 6 | 12 | |
| other | otitis | Infections and infestations | Placebo | 4 | 11 | |
| other | otitis | Infections and infestations | Ranitidine | 4 | 12 | |
| other | upper respiratory tract infection | Infections and infestations | Placebo | 4 | 11 | |
| other | upper respiratory tract infection | Infections and infestations | Ranitidine | 5 | 12 | |
| other | gastric ulcer | Gastrointestinal disorders | Placebo | 1 | 11 | |
| other | gastric ulcer | Gastrointestinal disorders | Ranitidine | 0 | 12 | |
| other | anemia | Blood and lymphatic system disorders | Placebo | 3 | 11 | |
| other | anemia | Blood and lymphatic system disorders | Ranitidine | 1 | 12 |
1 to 10 of 78Source ClinicalTrials.gov
See all 78 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Ranitidine | ||
| Total, other adverse events | Placebo | 10 | 11 |
| Total, other adverse events | Ranitidine | 11 | 12 |
| Total, serious adverse events | Placebo | 4 | 11 |
| Total, serious adverse events | Ranitidine | 4 | 12 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Ranitidine vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00527878
GET https://conductscience.org/api/trials/v1/NCT00527878/events?page=2